Yue-Meng Wan

Dr. Yue-Meng Wan


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2016 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
YLYu-Hua Li
Yu-Hua Li
YXYing Xu
Ying Xu
HWHua-Mei Wu
Hua-Mei Wu
JYJing Yang
Jing Yang
LYLi-Hong Yang
Li-Hong Yang
YWYue-Meng Wan
Yue-Meng Wan

19 October 2015 in Hepatology International
Verified
Journal Article
Closed access
PDF file
YWYue-Meng Wan
Yue-Meng Wan
LYLi-Hong Yang
Li-Hong Yang
YWYue-Meng Wan
Yue-Meng Wan
YXYing Xu
Ying Xu
JYJing Yang
Jing Yang
GSGui-Bo Song
Gui-Bo Song

17 March 2017 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
YWYue-Meng Wan
Yue-Meng Wan
YLYu‐Hua Li
Yu‐Hua Li
ZXZhi‐Yuan Xu
Zhi‐Yuan Xu
JYJing Yang
Jing Yang
LYLi‐Hong Yang
Li‐Hong Yang
YWYue-Meng Wan
Yue-Meng Wan

3 June 2015 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
YTYing-Mei Tang
Ying-Mei Tang
JWJia-Ping Wang
Jia-Ping Wang
WBWeimin Bao
Weimin Bao
YWYue-Meng Wan
Yue-Meng Wan
LMLin-Kun Ma
Lin-Kun Ma
JCJi-Bin Cheng
Ji-Bin Cheng
In order to provide non-invasive, reliable and sensitive laboratory parameters for the diagnosis of primary biliary cirrhosis (PBC), metabolic technology of ultraperformance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC/Q-TOF MS) was used to compare small molecule metabolites in blood and urine from patients with PBC and healthy controls. We then screened for bio-markers in the blood and urine of the patients with PBC. Data were processed by Bruker ProfileAnalysis metabonomic software and imported to SIMCA-P software, which utilized principal component analysis (PCA) to create models of patients with PBC and healthy controls. In total, 18 urinary markers were found and the levels of 11 of these urinary markers were elevated in the patients with PBC, whereas the levels of the remaining 7 markers were lower in the PBC group compared to the control group. We also identified 20 blood-based biomarkers in the patients with PBC and the levels of 9 of these markers were higher in the PBC group, whereas the levels of the remaining 11 markers were lower in the patients with PBC compared to the controls. Among these biomarkers, the levels of bile acids increased with the progression of PBC, while the levels of carnitines, such as propionyl carnitine and butyryl carnitine, decreased with the progression of PBC. In conclusion, the findings of the present study suggest that the circulating levels of bile acids and carnitine are differentially altered in patients with PBC.

21 July 2016 in Molecular Medicine Reports
Verified
Journal Article
Closed access
YTYing-Mei Tang
Ying-Mei Tang
WBWei-Min Bao
Wei-Min Bao
YWYue-Meng Wan
Yue-Meng Wan
LMLin-Kun Ma
Lin-Kun Ma
JYJing Yang
Jing Yang
YLYu-Hua Li
Yu-Hua Li
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

1 July 2018 in Academic Radiology
Verified
Journal Article
Closed access
YWYue-Meng Wan
Yue-Meng Wan
YLYu-Hua Li
Yu-Hua Li
YXYing Xu
Ying Xu
HWHua-Mei Wu
Hua-Mei Wu
YLYing-Chun Li
Ying-Chun Li
YWYue-Meng Wan
Yue-Meng Wan